dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Chibaudel, Benoist |
dc.contributor.author | Henriques, Julie |
dc.contributor.author | Rakez, Manel |
dc.contributor.author | Brenner, Baruch |
dc.contributor.author | Kim, Tae Won |
dc.contributor.author | Martínez-Villacampa, Mercedes |
dc.contributor.author | Tabernero Caturla, Josep |
dc.date.accessioned | 2021-09-22T13:06:38Z |
dc.date.available | 2021-09-22T13:06:38Z |
dc.date.issued | 2020-10-19 |
dc.identifier.citation | Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, et al. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer. JAMA Netw Open. 2020 Oct 19;3(10):e2020425. |
dc.identifier.issn | 2574-3805 |
dc.identifier.uri | https://hdl.handle.net/11351/6342 |
dc.description | Quimioteràpia; Supervivència sense malaltia; Càncer de còlon |
dc.description.sponsorship | This study was funded by Roche. |
dc.language.iso | eng |
dc.publisher | American Medical Association |
dc.relation.ispartofseries | Jama Network Open;3(10) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Còlon - Càncer |
dc.subject | Quimioteràpia combinada |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Colonic Neoplasms |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | /therapeutic use |
dc.subject.mesh | Disease-Free Survival |
dc.title | Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1001/jamanetworkopen.2020.20425 |
dc.subject.decs | neoplasias del colon |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | /uso terapéutico |
dc.subject.decs | supervivencia sin enfermedad |
dc.relation.publishversion | https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2771857 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Chibaudel B] Department of Medical Oncology, Franco-British Hospital–Fondation Cognacq-Jay, Levallois-Perret, France. Statistical Unit, Aide et Recherche en Cancérologie Digestive, Foundation, Levallois-Perret, France. [Henriques J] Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1098, Besançon, France. [Rakez M] Statistical Unit, Aide et Recherche en Cancérologie Digestive, Foundation, Levallois-Perret, France. [Brenner B] Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tiqva, Tel Aviv University, Tel Aviv, Israel. [Kim TW] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. [Martinez-Villacampa M] Department of Medical Oncology, Institut Català d'Oncologia-Bellvitge Institute for Biomedical Research, L’Hospitalet, Barcelona, Spain. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat de Vic–Universitat Central de Catalunya, International Oncology Bureau–Quiron, Barcelona, Spain |
dc.identifier.pmid | 33074326 |
dc.identifier.wos | 000586427500004 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |